

Does your drug reach the tumors cells?
In Heterogeneous tumor micro-environment, with different levels of vascularization, cellular densities, the Investigation of the drug penetration in the tumor tissue as well as the exposure of drugs to tumors cells are key parameters for the evaluation of a cancer treatment. These data will help to anticipate failure, to measure the potential of drug efficacy and optimize the dosing for future clinical trials. At ImaBiotech, we are able to quantify and localize drugs and metabolites in the targeted cells (tumor cells, immune cells) with the combination of different imaging modalities and our proprietary software called Multimaging. These unique innovations help you to define the potential applications of your treatment to different tumors types and cancers and reduce the risk of failure.
Moreover, we can measure the impact of the drug to tumor cells and companion biomakers to finally quantify the pharmacokinetics and pharmacodynamics at the site of action of the drugs for a precised measure of drug efficacy. This platform has been integrated into innovative in tissue PK/PD study to offer a better predictive tool.
What we deliver?
We deliver in a single experiment tissue distribution of drug, metabolites, targets and biomarkers of efficacy for a quick and precise drug efficacy and safety evaluation
Early Whole Body PK
- In vivo dosing
- Drugs distribution and concentration in Tumor Micro-Environment
- Drug and metabolites concentration in all organs
- Drug concentration in tumor cells, stroma and necrosis
- Pharmacokinetics in plasma
- Histology
Target Exposure
- In vivo dosing
- Drugs distribution and concentration in Tumor Micro-Environment
- Quantification and distribution of cell biomarkers
- Measure of immune cell infiltration (CD4, CD8)
In situ PK/PD
- In vivo dosing
- Drugs distribution and concentration in Tumor Micro-Environment
- Quantification and distribution of efficacy biomarker (metabolites, lipids, peptides, receptor, enzyme activities)
- Measure of immune cell infiltration (CD4, CD8)
- Statistical analysis to identify biomarker involved in tumor growth or drug responses
How do we reveal information in complex tissues?
ImaBiotech has developed an innovative platform including Mass Spectrometry Imaging, histology platform, laser capture micro-dissection, mass spectrometry, a dedicated software and a list of biomarkers to quantifiy drug and biomarker down to the micro-environment of the tumor. The platform is a combination of :
- Label free Mass Spectrometry Imaging at 10μm spatial resolution
- Laser Capture Micro-dissection
- Immuno-histology techniques
- Multimodal Dta Analysis Platform (Multimaging™, visit the dedicated page) with the ability to overlay MSI, IHC and HE images
- Efficacy and Safety Biomarkers monitoring
- High Resolution Mass Spectrometers (R>200,000)

Our Experiences?
Since Imabiotech have been founded, we measured and quantified around 200 drug dsitribution in tumors. In 90% of the case, the concentration of the drug, the penetration and the rate of exposure to tumor cells shown interesting features and the necessity to adapt the concenrtation and optimize conditions (formulations). We have experienced in large number of models (Orthotopic models and Xenograft tissues) in many applications (Breast Cancer, Colon Cancer, Brain Cancer, Prostate Cancer) from large to very small tissues (Core needle Biopsy) that allows ImaBiotech to perform preclinical, translational and clinical studies.
Resources
Testimonies

Jinping Gan
Senior Principal Scientist at BMS
,
Mika Pykäläinen
Head of Bioanalytical Operations, at Orion
,« Just one word: Excellent ! »

Oncology project in 2015
Anonymous
,« I have worked with ImaBiotech on some straightforward analyses and some that were a bit more challenging technically. In all cases, communication with ImaBiotech business and scientific personnel was excellent, and I feel confident that we obtained the best possible data given the experimental constraints we had to accommodate. »

Oncology project in 2016
Anonymous
,« Good quality work, very responsive and flexible team »
We also provide more classical studies under GLP or Non-GLP environment
PK & PD studies
We propose PK and PD studies to support early to late stages drug discovery process (animals: rabbit, dog, swine or other species upon customer request).
- Drug Disposition/Pharmacokinetics (ADME)
- DMPK
- Pharmacodynamics
- In Vitro and In Vivo Topical Absorption Studies (FFPE, 3D models, fresh frozen tissue)
Toxicology
We allow you to complete toxicological studies and propose several species such as dogs and rabbits and other non-rodent species.
- Acute Toxicity
- Subacute Toxicity (Repeated Dose)
- Sub-chronic Exposure
- Chronic Exposure
Models
We propose pathological models and naturally diseased animals for research (rabbit, dog …)